Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Holtzman

Showing results (281-290 of 293) with videos related to

Pageof 30
Sort By:
Blood|May 7, 2025
Phase 1/2 Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCTEduard Schulz, Lauren M Curtis, Noa G Holtzman, et al.
Neuro-Oncology|August 5, 2020
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomesNoa G Holtzman, Hao Xie, Soren Bentzen, et al.
Bone Marrow Transplantation|June 2, 2025
Psychosocial correlates of failure to complete hematopoietic stem cell transplants in a diverse populationMaria Rueda-Lara, Ingrid Barrera, Krishna V Komanduri, et al.
Biology|April 3, 2021
<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk StratificationAndrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
Mycopathologia|February 5, 2026
Clinical Characteristics and Outcomes of Invasive Aspergillosis in Patients with Hematological Malignancies and Transplantation and Cellular Therapies in the Contemporary EraChristopher M Lopez, Jose F Suarez, Maria A Mendoza, et al.
Blood Advances|April 26, 2024
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease preventionNoa G Holtzman, Lauren M Curtis, Rachel B Salit, et al.
Blood Advances|May 27, 2026
Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 studyNoa G Holtzman, Annie Im, Lauren M Curtis, et al.
British Journal of Haematology|September 9, 2021
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphomaForat Lutfi, Noa G Holtzman, Ankit J Kansagra, et al.
Ejhaem|March 11, 2021
Increased body mass index is a risk factor for acute promyelocytic leukemiaSarah M Kashanian, Andrew Y Li, Moaath Mustafa Ali, et al.
Transplantation and Cellular Therapy|January 15, 2026
Towards Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task ForceAlina Markova, Stephanie J Lee, Badri Modi, et al.
Pageof 30

Showing results (281-290 of 293) with videos related to

Sort By:
Pageof 30
Blood|May 7, 2025
Phase 1/2 Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCTEduard Schulz, Lauren M Curtis, Noa G Holtzman, et al.
Neuro-Oncology|August 5, 2020
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomesNoa G Holtzman, Hao Xie, Soren Bentzen, et al.
Bone Marrow Transplantation|June 2, 2025
Psychosocial correlates of failure to complete hematopoietic stem cell transplants in a diverse populationMaria Rueda-Lara, Ingrid Barrera, Krishna V Komanduri, et al.
Biology|April 3, 2021
<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk StratificationAndrew Y Li, Sarah M Kashanian, Bryan C Hambley, et al.
Mycopathologia|February 5, 2026
Clinical Characteristics and Outcomes of Invasive Aspergillosis in Patients with Hematological Malignancies and Transplantation and Cellular Therapies in the Contemporary EraChristopher M Lopez, Jose F Suarez, Maria A Mendoza, et al.
Blood Advances|April 26, 2024
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease preventionNoa G Holtzman, Lauren M Curtis, Rachel B Salit, et al.
Blood Advances|May 27, 2026
Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 studyNoa G Holtzman, Annie Im, Lauren M Curtis, et al.
British Journal of Haematology|September 9, 2021
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphomaForat Lutfi, Noa G Holtzman, Ankit J Kansagra, et al.
Ejhaem|March 11, 2021
Increased body mass index is a risk factor for acute promyelocytic leukemiaSarah M Kashanian, Andrew Y Li, Moaath Mustafa Ali, et al.
Transplantation and Cellular Therapy|January 15, 2026
Towards Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task ForceAlina Markova, Stephanie J Lee, Badri Modi, et al.
Pageof 30